Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler bought 15,000 shares of Accelerate Diagnostics stock in a transaction that occurred on Thursday, March 1st. The stock was purchased at an average cost of $25.15 per share, with a total value of $377,250.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Accelerate Diagnostics Inc (AXDX) traded up $0.45 during midday trading on Wednesday, hitting $25.85. The company’s stock had a trading volume of 120,464 shares, compared to its average volume of 268,328. The company has a market capitalization of $1,522.42, a PE ratio of -22.52 and a beta of 2.22. Accelerate Diagnostics Inc has a 12 month low of $16.75 and a 12 month high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.05. The company had revenue of $2.10 million during the quarter. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. analysts predict that Accelerate Diagnostics Inc will post -1.2 earnings per share for the current fiscal year.
Several research analysts recently commented on AXDX shares. BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. ValuEngine raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Accelerate Diagnostics currently has an average rating of “Hold” and a consensus target price of $33.00.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cpwm LLC bought a new position in shares of Accelerate Diagnostics during the fourth quarter valued at $202,000. UBS Asset Management Americas Inc. bought a new position in shares of Accelerate Diagnostics during the fourth quarter valued at $233,000. Teacher Retirement System of Texas bought a new position in shares of Accelerate Diagnostics during the fourth quarter valued at $292,000. MetLife Investment Advisors LLC bought a new position in shares of Accelerate Diagnostics during the fourth quarter valued at $297,000. Finally, Voya Investment Management LLC lifted its holdings in shares of Accelerate Diagnostics by 13.9% during the second quarter. Voya Investment Management LLC now owns 12,193 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 1,486 shares during the period. 44.86% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/14/accelerate-diagnostics-inc-axdx-director-purchases-377250-00-in-stock.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.